Search

Your search keyword '"van Gulik T"' showing total 1,037 results
Start Over Author "van Gulik T"
1,037 results on '"van Gulik T"'

125. Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract

Author

Roos, E, Soer, E C, Klompmaker, S, Meijer, Laura, Besselink, M G, Giovannetti, E, Heger, M, Kazemier, G, Klümpen, H J, Takkenberg, R B, Wilmink, H, Würdinger, T, Dijk, F, van Gulik, T M, Verheij, J, van de Vijver, M J, Afd Pharmaceutics, Sub Membrane Biochemistry & Biophysics, Pharmaceutics, Afd Pharmaceutics, Sub Membrane Biochemistry & Biophysics, and Pharmaceutics

Subjects
0301 basic medicine, Phosphofructokinase-2/genetics, Biliary Tract Neoplasms/genetics, Chromogranins/genetics, Phosphofructokinase-2, Cell of origin, Isocitrate Dehydrogenase/genetics, Phosphoric Monoester Hydrolases/genetics, Receptor, Transforming Growth Factor-beta Type II/genetics, Cholangiocarcinoma, 0302 clinical medicine, Neoplasm Proteins/genetics, GTP-Binding Protein alpha Subunits, Gs, Medicine, biology, Hematology, GTP-Binding Protein alpha Subunits, Isocitrate Dehydrogenase, Neoplasm Proteins, medicine.anatomical_structure, Biliary Tract Neoplasms, Oncology, Biliary tract, 030220 oncology & carcinogenesis, Cholangiocarcinoma/genetics, Receptor, GTP-Binding Protein alpha Subunits, Gs/genetics, IDH1, Adenomatous Polyposis Coli Protein, Genomics, IDH2, Transforming Growth Factor-beta Type II/genetics, 03 medical and health sciences, GNAS complex locus, Chromogranins, Humans, Adenomatous Polyposis Coli Protein/genetics, Membrane Proteins/genetics, Gene, business.industry, Gallbladder, Receptor, Transforming Growth Factor-beta Type II, Membrane Proteins, Phosphoric Monoester Hydrolases, Gs/genetics, 030104 developmental biology, Mutation, Cancer research, biology.protein, business
Abstract

Biliary tract carcinoma (BTC) comprises gallbladder and intra-/extrahepatic cholangiocarcinoma (GBC, ICC, EHC), which are currently classified by anatomical origin. Better understanding of the mutational profile of BTCs might refine classification and improve treatment. We performed a systematic review of studies reporting on mutational profiling of BTC. We included articles reporting on whole-exome/whole-genome-sequencing (WES/WGS) and targeted sequencing (TS) of BTC, published between 2000-2017. Pooled mutation proportions were calculated, stratified by anatomical region and sequencing technique. A total of 25 studies with 1806 patients were included. Overall, TP53 was the most commonly mutated gene in BTC. GBC was associated with mutations in PFKFB3, PLXN2 and PGAP1. Mutations in IDH1, IDH2 and FGFR fusions almost exclusively occurred in ICC patients. Mutations in APC, GNAS and TGFBR2 occurred exclusively in EHC patients. In conclusion, subtypes of BTCs exhibit minor differences in mutational profile, which is likely influenced by the cell of origin.

Published
2019
Full Text
View/download PDF

130. Does jaundice preclude resection in gallbladder cancer?

Author

De Savornin Lohman, E., primary, De Bitter, T., additional, Verhoeven, R., additional, Van laarhoven, C., additional, Erdmann, J., additional, Van der Post, R., additional, Koerkamp, B Groot, additional, Braat, A., additional, Van den Boezem, P., additional, Van Gulik, T., additional, and De Reuver, P., additional

Published
2020
Full Text
View/download PDF

138. Implementation and outcomes of a national liver surgeons expert panel to determine secondary resectability in patients with initially unresectable colorectal liver metastases (CRLM)

Author

Swijnenburg, R., primary, Bolhuis, K., additional, Huiskens, J., additional, Van Lienden, K., additional, Engelbrecht, M., additional, Van Amerongen, M., additional, Heijmen, L., additional, Hermans, J., additional, Molenaar, Q., additional, Verhoef, C., additional, Grünhagen, D., additional, De Jong, K., additional, Klaase, J., additional, Dejong, C., additional, Kazemier, G., additional, Ruers, T., additional, De Wilt, H., additional, Rijken, A., additional, Gerhards, M., additional, Liem, M., additional, Patijn, G., additional, Punt, C., additional, and Van Gulik, T., additional

Published
2020
Full Text
View/download PDF

141. Trends in incidence, treatment and survival of gallbladder cancer; a nation-wide cohort study

Author

De Savornin Lohman, E., primary, De Bitter, T., additional, Verhoeven, R., additional, Van der Geest, L., additional, Hagendoorn, J., additional, Mohammad, N Haj, additional, Daams, F., additional, Klumpen, H., additional, Van Gulik, T., additional, Erdmann, J., additional, De Boer, M., additional, Hoogwater, F., additional, Koerkamp, B Groot, additional, Braat, A., additional, Verheij, J., additional, Van laarhoven, C., additional, Nagtegaal, I., additional, Van den Boezem, P., additional, Van der Post, R., additional, and De Reuver, P., additional

Published
2020
Full Text
View/download PDF

142. Safety and efficacy of transarterial embolization of hepatocellular adenomas

Author

van Rosmalen, B V, primary, Klompenhouwer, A J, additional, de Graeff, J Jaap, additional, Haring, M P D, additional, de Meijer, V E, additional, Rifai, L, additional, Dokmak, S, additional, Rawashdeh, A, additional, Abu Hilal, M, additional, de Jong, M C, additional, Dejong, C H C, additional, Doukas, M, additional, de Man, R A, additional, IJzermans, J N M, additional, van Delden, O M, additional, Verheij, J, additional, and van Gulik, T M, additional

Published
2019
Full Text
View/download PDF

148. Post cholecystectomy bile duct injury : early, intermediate or late repair with hepaticojejunostomy - an E-AHPBA multi-center study

Author

Rystedt, Jenny M. L., Kleeff, Joerg, Salvia, Roberto, Besselink, Mark G., Prasad, Raj, Lesurtel, Mickael, Sturesson, Christian, Abu Hilal, M., Aljaiuossi, A., Antonucci, A., Ardito, F., Ausania, F., Bernon, M., Berrevoet, F., Bjornsson, B., Bonsing, B. A., Boonstra, E. A., Bracke, B., Brusadin, R., Burda, L., Caraballo, M., Casellas-Robert, M., Coker, A., Davide, J., De Gelder, A., De Rose, A. M., Djokic, M., Dudek, K., Ekmekcigil, E., Filauro, M., Fulop, A., Gallagher, T. K., Gastaca, M., Gefen, R., Giuliante, F., Habibeh, H., Halle-Smith, J., Haraldsdottir, K. H., Hartman, V, Hauer, A., Hemmingsson, O., Hoskovec, D., Isaksson, Bengt, Jonas, E., A, Khalaileh, Klug, R., Krige, J., Lignier, D., Lindemann, J., Lopez-Lopez, V, Lucidi, V, Mabrut, J-Y, Månsson, Christopher, Mieog, S., Mirza, D. F., Oldhafer, K. J., Omoshoro-Jones, J. A. O., Ortega-Torrecilla, N., Otto, W., Panaro, F., Pando, E., Paterna-Lopez, S., Pekmezci, S., Pesce, A., Porte, R. J., Poves, I, Prieto Calvo, M., Primavesi, F., Puleo, S., Recordare, A., Rizell, M., Roberts, K., Robles-Campos, R., Sanchiz-Cardenas, E., Sandstrom, P., Saribeyoglu, K., Schauer, M., Schreuder, M., Siriwardena, A. K., Smith, M. D., Silva, Sousa D., Sparrelid, E., Staettner, S., Stavrou, G. A., Straka, M., Stromberg, C., Sutcliffe, R. P., Szijarto, A., Taflin, H., Trotovsek, B., van Gulik, T., Wallach, N., Zieniewicz, K., Rystedt, Jenny M. L., Kleeff, Joerg, Salvia, Roberto, Besselink, Mark G., Prasad, Raj, Lesurtel, Mickael, Sturesson, Christian, Abu Hilal, M., Aljaiuossi, A., Antonucci, A., Ardito, F., Ausania, F., Bernon, M., Berrevoet, F., Bjornsson, B., Bonsing, B. A., Boonstra, E. A., Bracke, B., Brusadin, R., Burda, L., Caraballo, M., Casellas-Robert, M., Coker, A., Davide, J., De Gelder, A., De Rose, A. M., Djokic, M., Dudek, K., Ekmekcigil, E., Filauro, M., Fulop, A., Gallagher, T. K., Gastaca, M., Gefen, R., Giuliante, F., Habibeh, H., Halle-Smith, J., Haraldsdottir, K. H., Hartman, V, Hauer, A., Hemmingsson, O., Hoskovec, D., Isaksson, Bengt, Jonas, E., A, Khalaileh, Klug, R., Krige, J., Lignier, D., Lindemann, J., Lopez-Lopez, V, Lucidi, V, Mabrut, J-Y, Månsson, Christopher, Mieog, S., Mirza, D. F., Oldhafer, K. J., Omoshoro-Jones, J. A. O., Ortega-Torrecilla, N., Otto, W., Panaro, F., Pando, E., Paterna-Lopez, S., Pekmezci, S., Pesce, A., Porte, R. J., Poves, I, Prieto Calvo, M., Primavesi, F., Puleo, S., Recordare, A., Rizell, M., Roberts, K., Robles-Campos, R., Sanchiz-Cardenas, E., Sandstrom, P., Saribeyoglu, K., Schauer, M., Schreuder, M., Siriwardena, A. K., Smith, M. D., Silva, Sousa D., Sparrelid, E., Staettner, S., Stavrou, G. A., Straka, M., Stromberg, C., Sutcliffe, R. P., Szijarto, A., Taflin, H., Trotovsek, B., van Gulik, T., Wallach, N., and Zieniewicz, K.

Abstract

Background: Treatment of bile duct injuries (BDI) during cholecystectomy depends on the severity of injury and the timing of diagnosis. Standard of care for severe BDIs is hepaticojejunostomy. The aim of this retrospective multi-center study was to assess the optimal timing for repair of BDI with hepaticojejunostomy. Methods: Members of the European-African HepatoPancreatoBiliary Association were invited to report all consecutive patients with hepaticojejunostomy after BDI from January 2000 to June 2016. Patients were stratified according to the timing of biliary reconstruction with hepaticojejunostomy: early (day 0–7), intermediate (1–6 weeks) and late (6 weeks–6 months). Primary endpoint was re-intervention >90 days after the hepaticojejunostomy and secondary endpoints were severe 90-day complications and liver-related mortality. Results: In total 913 patients from 48 centers were included in the analysis. In 401 patients (44%) the bile duct injury was diagnosed intraoperatively, and 126 patients (14%) suffered from concomitant vascular injury. In multivariable analysis the timing of hepaticojejunostomy had no impact on postoperative complications, the need for re-intervention after 90 days nor liver-related mortality. The rate of re-intervention more than 90 days after the hepaticojejunostomy was significantly increased in male patients but decreased in older patients. Severe co-morbidity increased the risk for liver-related mortality (HR 3.439; CI 1.37–8.65; p = 0.009). Conclusion: After BDI occurring during cholecystectomy, the timing of biliary reconstruction with hepaticojejunostomy did not have any impact on severe postoperative complications, the need for re-intervention or liver-related mortality. Individualised treatment after iatrogenic bile duct injury is still advisable.

Published
2019
Full Text
View/download PDF

149. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial

Author

Garlipp, B., Gibbs, P., Van Hazel, G. A., Jeyarajah, R., Martin, R. C. G., Bruns, C. J., Lang, H., Manas, D. M., Ettorre, G. M., Pardo, F., Donckier, V., Benckert, C., van Gulik, T. M., Goere, D., Schoen, M., Pratschke, J., Bechstein, W. O., de la Cuesta, A. M., Adeyemi, S., Ricke, J., Seidensticker, M., Garlipp, B., Gibbs, P., Van Hazel, G. A., Jeyarajah, R., Martin, R. C. G., Bruns, C. J., Lang, H., Manas, D. M., Ettorre, G. M., Pardo, F., Donckier, V., Benckert, C., van Gulik, T. M., Goere, D., Schoen, M., Pratschke, J., Bechstein, W. O., de la Cuesta, A. M., Adeyemi, S., Ricke, J., and Seidensticker, M.

Abstract

Background Secondary resection of initially unresectable colorectal cancer liver metastases (CRLM) can prolong survival. The added value of selective internal radiotherapy (SIRT) to downsize lesions for resection is not known. This study evaluated the change in technical resectability of CRLM with the addition of SIRT to FOLFOX-based chemotherapy. Methods Baseline and follow-up hepatic imaging of patients who received modified FOLFOX (mFOLFOX6: fluorouracil, leucovorin, oxaliplatin) chemotherapy with or without bevacizumab (control arm) versus mFOLFOX6 (with or without bevacizumab) plus SIRT using yttrium-90 resin microspheres (SIRT arm) in the phase III SIRFLOX trial were reviewed by three or five (of 14) expert hepatopancreatobiliary surgeons for resectability. Reviewers were blinded to one another, treatment assignment, extrahepatic disease status, and information on clinical and scanning time points. Technical resectability was defined as at least 60 per cent of reviewers (3 of 5, or 2 of 3) assessing a patient's liver metastases as surgically removable. Results Some 472 patients were evaluable (SIRT, 244; control, 228). There was no significant baseline difference in the proportion of technically resectable liver metastases between SIRT (29, 11 center dot 9 per cent) and control (25, 11 center dot 0 per cent) arms (P = 0 center dot 775). At follow-up, significantly more patients in both arms were deemed technically resectable compared with baseline: 159 of 472 (33 center dot 7 per cent) versus 54 of 472 (11 center dot 4 per cent) respectively (P = 0 center dot 001). More patients were resectable in the SIRT than in the control arm: 93 of 244 (38 center dot 1 per cent) versus 66 of 228 (28 center dot 9 per cent) respectively (P < 0 center dot 001). Conclusion Adding SIRT to chemotherapy may improve the resectability of unresectable CRLM.

Published
2019

150. Effect of preoperative biliary drainage on cholestasis-associated inflammatory and fibrotic gene signatures in perihilar cholangiocarcinoma

Author

Sub Membrane Biochemistry & Biophysics, Afd Pharmaceutics, Pharmaceutics, Reiniers, M J, de Haan, L, Weijer, R, Wiggers, J K, Jongejan, A, Moerland, P D, Alles, L K, van Kampen, A H C, van Gulik, T M, Heger, M, van Golen, R F, Sub Membrane Biochemistry & Biophysics, Afd Pharmaceutics, Pharmaceutics, Reiniers, M J, de Haan, L, Weijer, R, Wiggers, J K, Jongejan, A, Moerland, P D, Alles, L K, van Kampen, A H C, van Gulik, T M, Heger, M, and van Golen, R F

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results